Prelude Therapeutics Incorporated reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 115.44 million compared to USD 111.69 million a year ago. Basic loss per share from continuing operations was USD 2.44 compared to USD 2.43 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 USD | -1.21% | +5.44% | -4.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.68% | 226M | |
+40.23% | 54.04B | |
+43.57% | 41.96B | |
-1.17% | 41.92B | |
-7.59% | 28.35B | |
+12.45% | 26.35B | |
-22.17% | 19B | |
+7.85% | 13B | |
+28.29% | 12.28B | |
+25.17% | 12.19B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022